PTPIPetros Pharmaceuticals, Inc.

Nasdaq petrospharma.com


$ 0.62 $ -0.02 (-3.36 %)    

Monday, 13-May-2024 13:13:06 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 0.6169
$ 0.63
$ 0.00 x 0
$ 0.67 x 100
$ 0.62 - $ 0.63
$ 0.60 - $ 5.24
156,007
na
1.34M
$ 1.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-01-2024 12-31-2023 10-K
2 11-15-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 petros-pharmaceuticals-inc-files-for-mixed-shelf-of-up-to-100m

- SEC Filing

 petros-pharmaceuticals-expands-online-distribution-for-prescription-stendra-through-new-agreement-with-lemonaid-health

Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED pa...

 petros-pharmaceuticals-receives-response-from-fda-following-recent-demonstration-of-technology-component-in-pursuit-of-otc-status-for-stendra

Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consume...

 why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

 petros-pharmaceuticals-q4-eps-217-misses-111-estimate-sales-36425k-miss-155m-estimate

Petros Pharmaceuticals (NASDAQ:PTPI) reported quarterly losses of $(2.17) per share which missed the analyst consensus estimate...

 petros-pharmaceuticals-successfully-launches-ai-tool-in-collaboration-with-multi-billion-dollar-software-provider-shares-spike-higher

Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDR...

 why-ups-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-e...

 why-super-micro-computer-shares-are-trading-higher-by-over-10-here-are-20-stocks-moving-premarket

Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted u...

 why-reshape-lifesciences-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket

Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA P...

 petros-pharmaceuticals-announces-completion-of-human-factors-study-to-facilitate-patients-access-to-its-erectile-dysfunction-drug-stendra-associated-with-the-companys-intended-fda-application-for-prescription-to-otc-switch

Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval

 petros-pharmaceuticals-partners-with-blockbuster-cholesterol-drug-crestors-otc-switch-technology-provider

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YOR...

 maxim-group-initiates-coverage-on-petros-pharma-with-buy-rating-announces-price-target-of-4

Maxim Group analyst Naz Rahman initiates coverage on Petros Pharma (NASDAQ:PTPI) with a Buy rating and announces Price Targe...

 petros-pharmaceuticals-partners-with-blockbuster-cholesterol-drug-crestors-otc-switch-technology-provider

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval

 petros-pharmaceuticals-petros-pharmaceuticals-developing-artificial-intelligence-technology-for-phase-2-equivalent-study-for-stendra

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the fi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION